This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Leoluca Criscione: Innovator in Pharmaceutical Research
Introduction
Leoluca Criscione is a notable inventor based in Möhlin, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the area of apoptosis stimulation. His work has implications for treating various pathological conditions.
Latest Patents
Leoluca Criscione holds 1 patent for his invention titled "AT1 receptor antagonist for the stimulation of apoptosis." This invention provides the use of an AT1 receptor antagonist, or a pharmaceutical salt thereof, for producing a pharmaceutical preparation aimed at stimulating apoptosis. The invention addresses the treatment of pathological symptoms that can be substantially reduced, halted, or prevented by apoptosis, along with corresponding pharmaceutical preparations.
Career Highlights
Leoluca Criscione is associated with Novartis AG, a leading global healthcare company. His role at Novartis has allowed him to work on innovative solutions that enhance patient care and treatment options.
Collaborations
Leoluca has collaborated with esteemed colleagues such as Gillian Rosemary Bullock and Marc De Gasparo. Their combined expertise contributes to the advancement of pharmaceutical research and development.
Conclusion
Leoluca Criscione's work in the pharmaceutical industry exemplifies the impact of innovative research on healthcare. His contributions, particularly in apoptosis stimulation, highlight the importance of scientific advancements in treating complex medical conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile